Professor Yang Liang:Research Progress and Reflections on BTK Inhibitors in the Treatment of CLL Patients | 2024 CSCO Hematology Academic Conference
In recent years, with the emergence of new targeted drugs such as ibrutinib and zanubrutinib, the treatment strategies for chronic lymphocytic leukemia (CLL) patients have been changing, sparking widespread discussions. At the recent 2024 CSCO Hematology Academic Conference, Professor Yang Liang from Sun Yat-sen University Cancer Center shared some thoughts on the classical international phase III clinical trial designs of BTK inhibitors and related issues. "Oncology Frontier - Hematology Frontier" specially invited Professor Yang Liang to discuss the progress in CLL treatment and the design of the ALPINE study.